Coya Therapeutics reports preclinical study shows COYA 303 combination cuts inflammation markers in LPS mouse model
COYA•Preclinical results for COYA 303 published
Coya Therapeutics disclosed publication of preclinical results for COYA 303, a combination therapy pairing low-dose IL-2 with a GLP-1 agonist.
Results were already presented via a peer-reviewed journal publication, not a future conference readout.
Mouse model showed broader anti-inflammatory effects
In an inflammation mouse model, the combination produced broader anti-inflammatory and immune-balancing effects than either agent alone.
Findings support further testing in more disease-relevant models, positioning COYA 303 as a potential combo approach for neurodegenerative diseases.
